{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:44:37Z","timestamp":1789670677952,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104764","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:01:56Z","timestamp":1773756116000},"page":"104764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-4876","authenticated-orcid":false,"given":"Nadine S.","family":"van den Ende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H.M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00428-022-03276-w","article-title":"Incorporation of TILs in daily breast cancer care: how much evidence can we bear?","volume":"480","author":"Laenkholm","year":"2022","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.breast.2026.104764_bib2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"13","key":"10.1016\/j.breast.2026.104764_bib4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"30","key":"10.1016\/j.breast.2026.104764_bib6","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.24.00372","article-title":"Academic uphill battle to personalize treatment for patients with stage II\/III triple-negative breast cancer","volume":"42","author":"Kok","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104764_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104764_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"van den Ende","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.breast.2026.104764_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14740\/wjon1019w","article-title":"The era of multigene panels comes? The clinical utility of oncotype DX and MammaPrint","volume":"8","author":"Xin","year":"2017","journal-title":"World J Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104764_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib11","first-page":"19","article-title":"Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104764_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104764_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology\/college of American pathologists guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.breast.2026.104764_bib15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104764_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104764_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2026.104764_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/ERC-19-0019","article-title":"PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer","volume":"26","author":"Agahozo","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104764_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2353\/jmoldx.2008.070153","article-title":"Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues","volume":"10","author":"Doleshal","year":"2008","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12859-018-2246-7","article-title":"Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons","volume":"19","author":"Smid","year":"2018","journal-title":"BMC Bioinf"},{"issue":"4","key":"10.1016\/j.breast.2026.104764_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-024-01774-0","article-title":"Tbcrc 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer","volume":"26","author":"Lynce","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2026.104764_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110138","article-title":"IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer","volume":"37","author":"Ka","year":"2021","journal-title":"Cell Rep"},{"issue":"7824","key":"10.1016\/j.breast.2026.104764_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","article-title":"Cancer SLC43A2 alters T cell methionine metabolism and histone methylation","volume":"585","author":"Bian","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib25","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41467-023-38750-9","article-title":"Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer","volume":"14","author":"Tundidor","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.breast.2026.104764_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100957","article-title":"Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers","volume":"47","author":"Lashen","year":"2024","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40659-020-00310-6","article-title":"Tumor suppressive function of Matrin 3 in the basal-like breast cancer","volume":"53","author":"Yang","year":"2020","journal-title":"Biol Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104764_bib28","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.26518","article-title":"Claudin-20 promotes an aggressive phenotype in human breast cancer cells","volume":"1","author":"Martin","year":"2013","journal-title":"Tissue Barriers"},{"issue":"2","key":"10.1016\/j.breast.2026.104764_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy\u2606","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104764_bib30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104764_bib31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","article-title":"The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition","volume":"32","author":"Loi","year":"2021","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104764_bib32","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16898-6","article-title":"HER2-low breast cancer shows a lower immune response compared to HER2-negative cases","volume":"12","author":"van den Ende","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.breast.2026.104764_bib34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.21873\/cdp.10463","article-title":"Clinical significance of HER2-low expression in triple-negative breast cancer: a retrospective multicenter study","volume":"5","author":"Iwai","year":"2025","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100009","article-title":"Interobserver variation in the assessment of immunohistochemistry expression levels in HER2-Negative breast cancer: can we improve the identification of low levels of HER2 expression by adjusting the criteria? An international interobserver study","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.breast.2026.104764_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13058-023-01739-9","article-title":"High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients","volume":"25","author":"Nielsen","year":"2023","journal-title":"Breast Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:57:55Z","timestamp":1778925475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S0960977626000743"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104764","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104764"}}